← Eichor
Study identifier: NCT04704115 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Therapy of Large Endometrioma

Condition: Endometrioma · Endometriosis Ovary  ·  Sponsor: University Hospital, Lille

PhaseN/A
Planned participants62
Who can joinFemale, 18 Years to 40 Years
Healthy volunteersNo

About this study

Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility and ovarian reserve. Currently, there's no recommendation about large endometrioma's treatment and there's no information on the best treatment to limit recurrences, preserve fertility and ovarian reserve. In Lille university hospital, simple laparoscopic drainage associated with hormonal therapy is practiced to reduce the risk of cystectomy. This protocol will be evaluated with an observational and prospective study, including women of childbearing age having endometrioma measuring 6 cm or above. The aim of this study is to assess if cyst drainage associated with GnRH agonist, could decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact on anti-mullerian hormone

This description comes directly from the study's public registry record.

Talk to the study team

Chrytèle RUBOD, MD,PhD  ·  0320445962  ·  chrystele.rubod@chru-lille.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hop Jeanne de Flandre Chu LilleLisle-sur-Tarn, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04704115